Developer docs
API playgroundTry for free, no card

Search company profiles

Isotopia

Full company profile

uuid000aiws

Namestring
Isotopia
Legal namestring
Isotopia Molecular Imaging Ltd.
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Isotopia Molecular Imaging Ltd. is an Israel-based radiopharmaceutical company that develops, manufactures, and distributes medical radioisotopes and radiopharmaceutical products for diagnostic imaging and targeted radionuclide therapy. Founded in 2012 as a collaboration between The Metrontario Group and Israeli scientists, the company is headquartered in Petach Tikva, Israel with 51–100 employees, and operates GMP-certified aseptic manufacturing across Petach Tikva and a newly relocated 2,000+ sqm facility in Modiin. It holds the first GPP-certified nuclear pharmacy in Israel and has cleared FDA inspection with a Drug Master File filed for non-carrier-added Lutetium-177.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPetah Tikwah, Israel
HQ citystring
Petah Tikwah
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiopharmaceutical manufacturing, medical radioisotope production, nuclear pharmacy services, PET imaging tracers, therapeutic radioligand supply
Industry6 codes
PRIMARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAE
Radiopharmacy Compounding & Dispensing (Hospital/Commercial)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Equipment and Supplies Manufacturing3391
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Radiopharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Radioisotope Product Sales
TypeOne Time License
Description

Sale of medical radioisotopes including Lutetium-177 (c.a. and n.c.a.), Terbium-161, and Gallium-68 to pharmaceutical companies, hospitals, and nuclear medicine departments for diagnostic imaging and targeted radionuclide therapy.

isotopia-global.com
2Radiopharmaceutical Cold Kits
TypeOne Time License
Description

Sale of ready-to-use radiolabeling kits including Isoprotrace (Ga-68 PSMA-11) for prostate cancer imaging and cold kits for radiopharmaceutical preparation.

isotopia-global.com
3Contract Manufacturing Organization (CMO) Services
TypeProfessional Services
Description

Aseptic manufacturing and fill-finish services for sterile drug preparations, cold kits, and radiopharmaceuticals for pharmaceutical partners. Services include product development, quality control, and regulatory support.

isotopia-global.com
4Clinical Supply Agreements
TypeTransaction Fee
Description

Supply of radioisotopes for clinical trials under GMP conditions to pharmaceutical companies developing radiopharmaceutical therapies. Long-term supply contracts ensuring 52 weeks per year production capacity.

isotopia-global.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels12 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1GMP-certified radioisotopes and radiopharmaceuticals
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products sold with GMP certification, FDA Drug Master File (DMF) support, and regulatory compliance documentation. Pricing varies by isotope type, activity level, and carrier status (CA vs NCA).

isotopia-global.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Isotopia develops, manufactures, and distributes diagnostic and therapeutic radiopharmaceuticals used in nuclear medicine and molecular imaging. Core offerings include Lutetium-177 (both carrier-added and non-carrier-added forms) for targeted radionuclide therapy, Terbium-161 as a next-generation therapeutic isotope, the Isoprotrace® Gallium-68 PSMA-11 radiolabeling kit for prostate cancer PET imaging, and F-18 DOPA PET tracers. The company also operates a GMP-certified aseptic manufacturing facility providing contract manufacturing (CMO) services for sterile radiopharmaceutical and injectable preparations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 68Ga-PSMA PET/CT demonstrated 92% accuracy compared to 65% accuracy for conventional CT and bone scan imaging in prostate cancer staging
+2 more records
Product overview1 text field

Isotopia is a global radiopharmaceutical company offering a comprehensive portfolio of diagnostic and therapeutic products for nuclear medicine. The core offerings include: Isoprotrace® (Gallium-68 PSMA-11 radiolabeling kit for prostate cancer PET imaging), Lutetium-177 (both n.c.a. and c.a. forms for targeted radionuclide therapy), and Terbium-161 (next-generation therapeutic isotope). Supporting products include PET and SPECT radiopharmaceuticals, cold kits, and calibration sources. The company operates manufacturing facilities in Israel (Petah Tikva and Modiin) providing aseptic manufacturing and CMO services for sterile drug production. Isotopia serves pharmaceutical companies and healthcare providers globally with production capabilities spanning from Israel to partnerships in North America, Europe, and Asia.

Product and service9 records
1Isoprotrace®
CategoryDiagnostic Radiopharmaceutical Kit
Description

Ready-to-use, multi-dose radiolabeling kit for preparation of Gallium-68 Gozetotide (68Ga-PSMA-11) used in PSMA PET/CT imaging of prostate cancer. Enables 1-vial, 1-step preparation with >95% radiochemical purity and approximately 5-minute preparation time.

2Lutetium-177 (Lu-177) — n.c.a. and c.a.
CategoryTherapeutic Radioisotope
Description

Therapeutic radioisotope supplied in both non-carrier-added (n.c.a.) and carrier-added (c.a.) forms as GMP-grade Lu-177 chloride. N.c.a. Lu-177 contains no metastable Lu-177m impurities, eliminating cost-intensive clinical waste management. Used in targeted radionuclide therapy for neuroendocrine tumors and prostate cancer.

3Terbium-161
CategoryTherapeutic Radioisotope
Description

Next-generation therapeutic radioisotope emitting both beta radiation and Auger electrons for targeted cancer treatment. Developed using Gadolinium-160 target material, with advantages over Lu-177 for targeting micrometastases. Used in clinical trials for prostate cancer and neuroendocrine tumors.

4F-18 DOPA
CategoryPET Radiopharmaceutical
Description

PET radiotracer (Fluorine-18 DOPA) for imaging dopaminergic neurons in the brain and detection of neuroendocrine tumors. Used for evaluation of Parkinsonian syndromes and diagnosis of neuroendocrine tumors including pheochromocytoma, paraganglioma, neuroblastoma, and infant insulinemia.

5PET Radiopharmaceutical Products
CategoryPET Radiopharmaceuticals
Description

Portfolio of PET (Positron Emission Tomography) radiopharmaceuticals including F-18 DOPA for neuroendocrine tumors and Parkinson's disease diagnosis, and Ga-68 based tracers for diagnostic imaging.

6SPECT Radiopharmaceutical Products
CategorySPECT Radiopharmaceuticals
Description

Single Photon Emission Computed Tomography (SPECT) radiopharmaceutical products for diagnostic imaging across various clinical applications.

7Cold Kits
CategoryRadiolabeling Cold Kits
Description

Radiopharmaceutical cold kits for convenient preparation of diagnostic tracers in clinical settings, including kits for Ga-68 radiolabeling and other isotopes used in nuclear medicine imaging.

8Lu177 Treatment Services
CategoryTherapeutic Radiopharmaceutical Service
Description

Radiopharmaceutical treatment preparations based on Lutetium-177 for targeted radionuclide therapy of cancers including neuroendocrine tumors and prostate cancer.

9Aseptic Manufacturing / CMO Services
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership19 partners
1M.G.P. spol. s r.o. (Czech Republic)
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-20
Description

Official distributor for Isoprotrace in the Czech Republic providing comprehensive nuclear medicine solutions from imaging equipment to radiopharmaceuticals.

isotopia-global.com
2Peter MacCallum Cancer Centre (ProsTIC)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-31
Description

Clinical research and supply agreement for n.c.a. Tb-161 for first-in-human pilot study. Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) will conduct trial linking 161Tb to PSMA for advanced prostate cancer treatment.

isotopia-global.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-10-19
Description

Strategic collaboration for supply of n.c.a. 177Lu to support Sinotau's clinical development pipeline in China. Sinotau has manufacturing sites in Jiangsu, Guangdong, Sichuan with plans for commercialization.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-08
Description

Production agreement for 177Lu n.c.a. at Austria facility. Selected after year-long evaluation for high GMP infrastructure and expertise. Expected commercial-scale production by Q4 2022 with easy land transport access to European market.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-09-01
Description

Collaboration focused on dosimetry and personalized medicine. HMS provides quantitative imaging and dosimetry software expertise while Isotopia contributes radiopharmaceutical innovation. Joint development of dosimetry tools for Tb-161 therapeutic isotope.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-07-21
Description

Clinical supply agreement for n.c.a. Lu-177 for use in POINT's PNT2002 PSMA-targeting drug for mCRPC. Lu-177 will be used at POINT's Indianapolis facility for clinical trials including Phase 3 SPLASH trial.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2021-05-20
Description

Research collaboration with Prof. Sharon Ruthstein to develop hypoxia radioactive marker based on Copper-64 isotope for detecting oxygen-deficient cells and tumor aggressiveness. Part of Innovation Authority's Magneton Program.

8Elgan Pharma
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2021-05-06
Description

Strategic agreement for Phase III and commercial CMO services for lyophilized product manufacturing. Isotopia provides sterile production with high GMP compliance for Elgan's neonatology therapies.

isotopia-global.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-03-16
Description

Strategic commercial partnership with exclusive license to market Isotopia's theranostic products in the US. Combines Isotopia's innovation with Jubilant's 49-radiopharmacy network for North American market expansion.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-03-10
Description

Clinical supply agreement for n.c.a. 177Lu to support development of 177Lu-EBTATE for neuroendocrine tumors and 177Lu-EBRGD for GBM and NSCLC using Evans Blue platform technology.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2021-01-19
Description

Technology partnership for multi-curie radiolabeling of PSMA-11 with cyclotron-produced Ga-68 using ARTMS' Quantum Irradiation System (QIS). Successful labeling with 500-2900 mCi of 68Ga demonstrating 6-hour stability.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-11-08
Description

Clinical supply collaboration for n.c.a. 177Lu to support development of 177Lu-DTPA-omburtamab for B7-H3 positive CNS and leptomeningeal metastasis treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-09-08
Description

Production and distribution partnership for n.c.a. Lu-177 in North America. CPDC produces Lu-177 at Hamilton, Ontario facility. Expansion planned to NuGeneris Specialty Pharmaceuticals for commercial-scale production.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-02-10
Description

Development partnership to finalize PSMA-11 Kit development for prostate cancer imaging. Collaboration to make operation feasible on E&Z's KitLab with GalliaPharm 68Ge/68Ga generator in the DMF and EU marketing authorization.

15CNIC (Canadian Nuclear Isotope Council)
Strategic tierFoundationalTypeStrategic or Co-development PartnerAnnounced on2019-11-01
Description

Global partnership to ensure reliable and secure supply of life-saving medical isotopes. CNIC is an independent body representing Canadian health sector, nuclear industry, and research groups. Supports Isotopia's mission to develop and manufacture radiopharmaceutical treatments for patients globally.

isotopia-global.com
16DSD Pharma (Germany)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Official commercial launch partner for Isoprotrace in Germany with marketing authorization.

isotopia-global.com
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner for Isoprotrace launch in Sweden and Denmark expanding Nordic market access.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Strategic agreement for clinical contract manufacturing services.

19Isotopia USA (E Solutions and Comfort Systems)
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

US market partnerships for operations and distribution support.

isotopia-global.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global incumbent offering a broad radiopharma portfolio (SPECT/PET tracers, contrast media) plus PETNET Solutions radiopharmacy network. Operates at much greater scale and overlaps with Isotopia across diagnostic imaging tracers and radiopharmacy distribution.

TypeBroad incumbent
Description

Operates a large network of PET radiopharmacy sites producing FDG and other PET tracers across the US and Europe. Directly comparable to Isotopia's PET/SPECT radiopharmacy and cold kit business.

TypeBroad incumbent
Description

Operates one of the largest US radiopharmacy networks distributing nuclear medicine products to hospitals. Comparable to Jubilant (Isotopia's exclusive US partner) and competes in the same downstream distribution layer.

TypeBroad incumbent
Description

Global diagnostic imaging company with a meaningful radiopharmaceutical and contrast media portfolio. Overlaps with Isotopia in nuclear medicine diagnostic products and shares pharmaceutical/hospital channels.

TypeDirect peer
Description

Owns Pluvicto (Lu-177 vipivotide) and Lutathera, the leading Lu-177-based radioligand therapies, and operates large-scale Lu-177 production. A direct vertical competitor and a customer class for Isotopia's Lu-177 supply (Novartis also sources externally).

TypeDirect peer
Description

One of the world's largest nuclear medicine companies, producing SPECT/PET diagnostic and therapeutic radiopharmaceuticals including Mo-99/Tc-99m and Lu-177. Directly competes with Isotopia in the Lu-177 supply market and shares the same pharma customer base.

TypeDirect peer
Description

Diagnostic radiopharmaceutical company focused on PET and SPECT tracers, including Pylarify (piflufolastat F-18, a direct PSMA PET competitor to Isotopia's Isoprotrace Ga-68 PSMA-11 kit). Comparable in prostate cancer imaging focus.

TypeDirect peer
Description

Theranostic-focused radiopharma company developing Lu-177-based therapies (TLX591, TLX592) and Illuccix (Ga-68 PSMA-11 kit) — the latter is a direct head-to-head competitor to Isotopia's Isoprotrace product.

TypeDirect peer
Description

European producer of medical radioisotopes including Lu-177 and radiopharmaceutical kits for targeted radionuclide therapy. Direct competitor in the Lu-177 supply market with similar theranostics focus and GMP-certified production.

TypeBroad incumbent
Description

Bayer's radiopharma franchise (including Xofigo, Ra-223 dichloride) is supplied in partnership with Curium, making it both a competitor and a comparable end-customer class for therapeutic radioisotope suppliers like Isotopia.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Isotopia

Radiopharmaceuticalsisotopia-global.com

What Isotopia does

Isotopia Molecular Imaging Ltd. is an Israel-based radiopharmaceutical company that develops, manufactures, and distributes medical radioisotopes and radiopharmaceutical products for diagnostic imaging and targeted radionuclide therapy. Founded in 2012 as a collaboration between The Metrontario Group and Israeli scientists, the company is headquartered in Petach Tikva, Israel with 51–100 employees, and operates GMP-certified aseptic manufacturing across Petach Tikva and a newly relocated 2,000+ sqm facility in Modiin. It holds the first GPP-certified nuclear pharmacy in Israel and has cleared FDA inspection with a Drug Master File filed for non-carrier-added Lutetium-177.

Isotopia firmographics

Firmographics
Name
Isotopia
Legal name
Isotopia Molecular Imaging Ltd.
Website
https://isotopia-global.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Isotopia industry classification

Industry
Product category
Radiopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAGAC
Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAD
Radioisotope Production (Reactor/Cyclotron/Gamma)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAE
Radiopharmacy Compounding & Dispensing (Hospital/Commercial)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAA
Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)

Keywords

  • Radiopharmaceutical manufacturing
  • Medical radioisotope production
  • Nuclear pharmacy services
  • PET imaging tracers
  • Therapeutic radioligand supply

Where Isotopia is headquartered

Location

Headquarters

HQ city
Petah Tikwah
HQ country
Israel
HQ region
Middle East

Offices3 records

Markets served

Isotopia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Radioisotope Product Sales: Sale of medical radioisotopes including Lutetium-177 (c.a. and n.c.a.), Terbium-161, and Gallium-68 to pharmaceutical companies, hospitals, and nuclear medicine departments for diagnostic imaging and targeted radionuclide therapy.
  2. Radiopharmaceutical Cold Kits: Sale of ready-to-use radiolabeling kits including Isoprotrace (Ga-68 PSMA-11) for prostate cancer imaging and cold kits for radiopharmaceutical preparation.
  3. Contract Manufacturing Organization (CMO) Services: Aseptic manufacturing and fill-finish services for sterile drug preparations, cold kits, and radiopharmaceuticals for pharmaceutical partners. Services include product development, quality control, and regulatory support.
  4. Clinical Supply Agreements: Supply of radioisotopes for clinical trials under GMP conditions to pharmaceutical companies developing radiopharmaceutical therapies. Long-term supply contracts ensuring 52 weeks per year production capacity.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goGMP-certified radioisotopes and radiopharmaceuticals

Go-to-market motion3 records

Distribution channels12 records

Marketing channels10 records

Isotopia product offering

Product offering

Core offering

Isotopia develops, manufactures, and distributes diagnostic and therapeutic radiopharmaceuticals used in nuclear medicine and molecular imaging. Core offerings include Lutetium-177 (both carrier-added and non-carrier-added forms) for targeted radionuclide therapy, Terbium-161 as a next-generation therapeutic isotope, the Isoprotrace® Gallium-68 PSMA-11 radiolabeling kit for prostate cancer PET imaging, and F-18 DOPA PET tracers. The company also operates a GMP-certified aseptic manufacturing facility providing contract manufacturing (CMO) services for sterile radiopharmaceutical and injectable preparations.

Product overview

Isotopia is a global radiopharmaceutical company offering a comprehensive portfolio of diagnostic and therapeutic products for nuclear medicine. The core offerings include: Isoprotrace® (Gallium-68 PSMA-11 radiolabeling kit for prostate cancer PET imaging), Lutetium-177 (both n.c.a. and c.a. forms for targeted radionuclide therapy), and Terbium-161 (next-generation therapeutic isotope). Supporting products include PET and SPECT radiopharmaceuticals, cold kits, and calibration sources. The company operates manufacturing facilities in Israel (Petah Tikva and Modiin) providing aseptic manufacturing and CMO services for sterile drug production. Isotopia serves pharmaceutical companies and healthcare providers globally with production capabilities spanning from Israel to partnerships in North America, Europe, and Asia.

Differentiator

Problem solved

Functional benefit

Products and services

  • Isoprotrace® Ready-to-use, multi-dose radiolabeling kit for preparation of Gallium-68 Gozetotide (68Ga-PSMA-11) used in PSMA PET/CT imaging of prostate cancer. Enables 1-vial, 1-step preparation with >95% radiochemical purity and approximately 5-minute preparation time.
  • Lutetium-177 (Lu-177) — n.c.a. and c.a. Therapeutic radioisotope supplied in both non-carrier-added (n.c.a.) and carrier-added (c.a.) forms as GMP-grade Lu-177 chloride. N.c.a. Lu-177 contains no metastable Lu-177m impurities, eliminating cost-intensive clinical waste management. Used in targeted radionuclide therapy for neuroendocrine tumors and prostate cancer.
  • Terbium-161 Next-generation therapeutic radioisotope emitting both beta radiation and Auger electrons for targeted cancer treatment. Developed using Gadolinium-160 target material, with advantages over Lu-177 for targeting micrometastases. Used in clinical trials for prostate cancer and neuroendocrine tumors.
  • F-18 DOPA PET radiotracer (Fluorine-18 DOPA) for imaging dopaminergic neurons in the brain and detection of neuroendocrine tumors. Used for evaluation of Parkinsonian syndromes and diagnosis of neuroendocrine tumors including pheochromocytoma, paraganglioma, neuroblastoma, and infant insulinemia.
  • PET Radiopharmaceutical Products Portfolio of PET (Positron Emission Tomography) radiopharmaceuticals including F-18 DOPA for neuroendocrine tumors and Parkinson's disease diagnosis, and Ga-68 based tracers for diagnostic imaging.
  • SPECT Radiopharmaceutical Products Single Photon Emission Computed Tomography (SPECT) radiopharmaceutical products for diagnostic imaging across various clinical applications.
  • Cold Kits Radiopharmaceutical cold kits for convenient preparation of diagnostic tracers in clinical settings, including kits for Ga-68 radiolabeling and other isotopes used in nuclear medicine imaging.
  • Lu177 Treatment Services Radiopharmaceutical treatment preparations based on Lutetium-177 for targeted radionuclide therapy of cancers including neuroendocrine tumors and prostate cancer.
  • Aseptic Manufacturing / CMO Services

Quantifiable outcome

  • 68Ga-PSMA PET/CT demonstrated 92% accuracy compared to 65% accuracy for conventional CT and bone scan imaging in prostate cancer staging
  • +2 more outcomes

Companies that use Isotopia

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Isotopia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

Isotopia partnerships and signals

Strategic signal

Partnerships

19 partnerships are on record, tiered regional, core, minor and foundational.

  • M.G.P. spol. s r.o. (Czech Republic)regionalChannel Partner/ Reseller/ Distributor · 20 May 2026Official distributor for Isoprotrace in the Czech Republic providing comprehensive nuclear medicine solutions from imaging equipment to radiopharmaceuticals.
  • Peter MacCallum Cancer Centre (ProsTIC)coreStrategic or Co-development Partner · 31 October 2021Clinical research and supply agreement for n.c.a. Tb-161 for first-in-human pilot study. Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) will conduct trial linking 161Tb to PSMA for advanced prostate cancer treatment.
  • Sinotau PharmaceuticalscoreTechnology or Integration · 19 October 2021Strategic collaboration for supply of n.c.a. 177Lu to support Sinotau's clinical development pipeline in China. Sinotau has manufacturing sites in Jiangsu, Guangdong, Sichuan with plans for commercialization.
  • Seibersdorf Labor GmbHcoreStrategic or Co-development Partner · 8 October 2021Production agreement for 177Lu n.c.a. at Austria facility. Selected after year-long evaluation for high GMP infrastructure and expertise. Expected commercial-scale production by Q4 2022 with easy land transport access to European market.
  • HERMES Medical SolutionsminorStrategic or Co-development Partner · 1 September 2021Collaboration focused on dosimetry and personalized medicine. HMS provides quantitative imaging and dosimetry software expertise while Isotopia contributes radiopharmaceutical innovation. Joint development of dosimetry tools for Tb-161 therapeutic isotope.
  • POINT BiopharmacoreTechnology or Integration · 21 July 2021Clinical supply agreement for n.c.a. Lu-177 for use in POINT's PNT2002 PSMA-targeting drug for mCRPC. Lu-177 will be used at POINT's Indianapolis facility for clinical trials including Phase 3 SPLASH trial.
  • Bar-Ilan UniversityminorStrategic or Co-development Partner · 20 May 2021Research collaboration with Prof. Sharon Ruthstein to develop hypoxia radioactive marker based on Copper-64 isotope for detecting oxygen-deficient cells and tumor aggressiveness. Part of Innovation Authority's Magneton Program.
  • Elgan PharmaminorImplementation/ SI/ Consulting Partner · 6 May 2021Strategic agreement for Phase III and commercial CMO services for lyophilized product manufacturing. Isotopia provides sterile production with high GMP compliance for Elgan's neonatology therapies.
  • Jubilant RadiopharmacoreChannel Partner/ Reseller/ Distributor · 16 March 2021Strategic commercial partnership with exclusive license to market Isotopia's theranostic products in the US. Combines Isotopia's innovation with Jubilant's 49-radiopharmacy network for North American market expansion.
  • M.T.T.I (Molecular Targeting Technologies)coreTechnology or Integration · 10 March 2021Clinical supply agreement for n.c.a. 177Lu to support development of 177Lu-EBTATE for neuroendocrine tumors and 177Lu-EBRGD for GBM and NSCLC using Evans Blue platform technology.
  • ARTMScoreTechnology or Integration · 19 January 2021Technology partnership for multi-curie radiolabeling of PSMA-11 with cyclotron-produced Ga-68 using ARTMS' Quantum Irradiation System (QIS). Successful labeling with 500-2900 mCi of 68Ga demonstrating 6-hour stability.
  • Y-mAbs TherapeuticscoreTechnology or Integration · 8 November 2020Clinical supply collaboration for n.c.a. 177Lu to support development of 177Lu-DTPA-omburtamab for B7-H3 positive CNS and leptomeningeal metastasis treatment.
  • CPDC (Centre for Probe Development and Commercialization)coreStrategic or Co-development Partner · 8 September 2020Production and distribution partnership for n.c.a. Lu-177 in North America. CPDC produces Lu-177 at Hamilton, Ontario facility. Expansion planned to NuGeneris Specialty Pharmaceuticals for commercial-scale production.
  • Eckert & ZieglercoreStrategic or Co-development Partner · 10 February 2020Development partnership to finalize PSMA-11 Kit development for prostate cancer imaging. Collaboration to make operation feasible on E&Z's KitLab with GalliaPharm 68Ge/68Ga generator in the DMF and EU marketing authorization.
  • CNIC (Canadian Nuclear Isotope Council)foundationalStrategic or Co-development Partner · 1 November 2019Global partnership to ensure reliable and secure supply of life-saving medical isotopes. CNIC is an independent body representing Canadian health sector, nuclear industry, and research groups. Supports Isotopia's mission to develop and manufacture radiopharmaceutical treatments for patients globally.
  • DSD Pharma (Germany)regionalChannel Partner/ Reseller/ DistributorOfficial commercial launch partner for Isoprotrace in Germany with marketing authorization.
  • Cardirad (Sweden and Denmark)regionalChannel Partner/ Reseller/ DistributorDistribution partner for Isoprotrace launch in Sweden and Denmark expanding Nordic market access.
  • Immunity Pharma Ltd (IPL)minorImplementation/ SI/ Consulting PartnerStrategic agreement for clinical contract manufacturing services.
  • Isotopia USA (E Solutions and Comfort Systems)regionalChannel Partner/ Reseller/ DistributorUS market partnerships for operations and distribution support.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Isotopia competitors and assessment

Company assessment

Broad incumbents

  • GE HealthCare: Global incumbent offering a broad radiopharma portfolio (SPECT/PET tracers, contrast media) plus PETNET Solutions radiopharmacy network. Operates at much greater scale and overlaps with Isotopia across diagnostic imaging tracers and radiopharmacy distribution.
  • PETNET Solutions (Siemens Healthineers): Operates a large network of PET radiopharmacy sites producing FDG and other PET tracers across the US and Europe. Directly comparable to Isotopia's PET/SPECT radiopharmacy and cold kit business.
  • Cardinal Health (Nuclear Pharmacy Services): Operates one of the largest US radiopharmacy networks distributing nuclear medicine products to hospitals. Comparable to Jubilant (Isotopia's exclusive US partner) and competes in the same downstream distribution layer.
  • Bracco Imaging: Global diagnostic imaging company with a meaningful radiopharmaceutical and contrast media portfolio. Overlaps with Isotopia in nuclear medicine diagnostic products and shares pharmaceutical/hospital channels.
  • Bayer (with Curium): Bayer's radiopharma franchise (including Xofigo, Ra-223 dichloride) is supplied in partnership with Curium, making it both a competitor and a comparable end-customer class for therapeutic radioisotope suppliers like Isotopia.

Direct peers

  • Novartis (Advanced Accelerator Applications / AAA): Owns Pluvicto (Lu-177 vipivotide) and Lutathera, the leading Lu-177-based radioligand therapies, and operates large-scale Lu-177 production. A direct vertical competitor and a customer class for Isotopia's Lu-177 supply (Novartis also sources externally).
  • Curium Pharma: One of the world's largest nuclear medicine companies, producing SPECT/PET diagnostic and therapeutic radiopharmaceuticals including Mo-99/Tc-99m and Lu-177. Directly competes with Isotopia in the Lu-177 supply market and shares the same pharma customer base.
  • Lantheus Holdings: Diagnostic radiopharmaceutical company focused on PET and SPECT tracers, including Pylarify (piflufolastat F-18, a direct PSMA PET competitor to Isotopia's Isoprotrace Ga-68 PSMA-11 kit). Comparable in prostate cancer imaging focus.
  • Telix Pharmaceuticals: Theranostic-focused radiopharma company developing Lu-177-based therapies (TLX591, TLX592) and Illuccix (Ga-68 PSMA-11 kit) — the latter is a direct head-to-head competitor to Isotopia's Isoprotrace product.
  • ITM Isotope Technologies Munich: European producer of medical radioisotopes including Lu-177 and radiopharmaceutical kits for targeted radionuclide therapy. Direct competitor in the Lu-177 supply market with similar theranostics focus and GMP-certified production.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Isotopia social profiles

Digital presence

Isotopia compliance and trust

Trust signal

Compliance5 records

Isotopia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Isotopia leadership team

Management profile

Number of profiles

Profiles9 records

Isotopia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Isotopia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Isotopia

What does Isotopia do?

Isotopia develops, manufactures, and distributes diagnostic and therapeutic radiopharmaceuticals used in nuclear medicine and molecular imaging. Core offerings include Lutetium-177 (both carrier-added and non-carrier-added forms) for targeted radionuclide therapy, Terbium-161 as a next-generation therapeutic isotope, the Isoprotrace® Gallium-68 PSMA-11 radiolabeling kit for prostate cancer PET imaging, and F-18 DOPA PET tracers. The company also operates a GMP-certified aseptic manufacturing facility providing contract manufacturing (CMO) services for sterile radiopharmaceutical and injectable preparations.

Is Isotopia a public or private company?

Isotopia is a private company. It is classified as corporate owned and is currently operating.

When was Isotopia founded?

Isotopia was founded in 2012. It employs 101 to 250 people.

Where is Isotopia based?

Isotopia is headquartered in Petah Tikwah, Israel, in the Middle East region.

How does Isotopia make money?

Four revenue lines are on record. Radioisotope Product Sales are the primary driver. The others are radiopharmaceutical Cold Kits, contract Manufacturing Organization (CMO) Services and clinical Supply Agreements.

Who are Isotopia's main competitors?

Broad incumbents on record are GE HealthCare, PETNET Solutions (Siemens Healthineers), Cardinal Health (Nuclear Pharmacy Services), Bracco Imaging and Bayer (with Curium). Direct peers are Novartis (Advanced Accelerator Applications / AAA), Curium Pharma, Lantheus Holdings, Telix Pharmaceuticals and ITM Isotope Technologies Munich.

Does Isotopia have an API?

No public API is recorded for Isotopia.

What industry is Isotopia in?

Isotopia's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx), with a secondary code of HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 3254 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireIsotopia Announces the UK Launch of Isoprotrace®, an Innovative Diagnostic Solution for Prostate Cancer ImagingIsotopia Molecular Imaging launched Isoprotrace, a Gallium-68 Gozetotide kit for prostate cancer imaging, in the UK. The ready-to-use kit is distributed via Light Medical, aiming to improve diagnostic accuracy and treatment outcomes. Isotopia pledged to maintain a robust supply chain for healthcare providers.Business & FinancialIsotopia Announces The UK Launch Of Isoprotrace®, An Innovative Diagnostic Solution For Prostate Cancer ImagingIsotopia Molecular Imaging launched Isoprotrace, a Gallium-68 Gozetotide kit for prostate cancer imaging, in the UK. The ready-to-use kit is distributed via Light Medical, aiming to improve diagnostic accuracy and treatment outcomes. Isotopia pledged to maintain a robust supply chain for healthcare providers.PR NewswireIsotopia Announces the UK Launch of Isoprotrace®, an Innovative Diagnostic Solution for Prostate Cancer ImagingIsotopia Molecular Imaging launched Isoprotrace, a Gallium-68 Gozetotide kit for prostate cancer imaging, in the UK. The ready-to-use kit is distributed via Light Medical, aiming to improve diagnostic accuracy and treatment outcomes.PR NewswireIsotopia Announces the UK Launch of Isoprotrace®, an Innovative Diagnostic Solution for Prostate Cancer ImagingIsotopia Molecular Imaging launched Isoprotrace, a Gallium-68 Gozetotide kit for prostate cancer imaging, in the UK. The ready-to-use kit is distributed via Light Medical, aiming to improve diagnostic accuracy and treatment outcomes.PR NewswireIsotopia Announces Official Commercial Launch of Isoprotrace® in Germany in Partnership with DSD PharmaIsotopia officially launched Isoprotrace in Germany, with DSD Pharma as exclusive distributor. The radiopharmaceutical is for prostate cancer imaging and is expected to be available soon in over 10 EU countries.YahooIsotopia Announces Official Commercial Launch of Isoprotrace® in Germany in Partnership with DSD PharmaIsotopia officially launched Isoprotrace in Germany, with DSD Pharma as exclusive distributor. The radiopharmaceutical is for prostate cancer imaging, and Isotopia also distributes Lutetium (177 Lu) Chloride n.c.a. The product is expected to be available soon in over 10 EU countries.PR NewswireIsotopia Announces Official Commercial Launch of Isoprotrace® in Germany in Partnership with DSD PharmaIsotopia officially launched Isoprotrace in Germany, with DSD Pharma as exclusive distributor. The radiopharmaceutical is for prostate cancer imaging and is expected to be available soon in over 10 EU countries.PR NewswireKinectrics and Isotopia Enter Agreement for Supply of Gadolinium-160 (Gd-160) to Support Production of Terbium-161 (Tb-161) for Advanced RadiotherapeuticsKinectrics and Isotopia announced a partnership agreement under which Kinectrics will supply Gadolinium-160 (Gd-160) to enable Isotopia's production of Terbium-161 (Tb-161), a medical isotope showing promise for radiotherapeutics targeting prostate and neuroendocrine tumors. This agreement addresses a critical bottleneck that has historically limited advancement of Tb-161-based treatments into clinical trials. The partnership is expected to accelerate development of Tb-161-based radiotherapeutics, moving them closer to commercial availability for cancer treatment.PR NewswireKinectrics and Isotopia Enter Agreement for Supply of Gadolinium-160 (Gd-160) to Support Production of Terbium-161 (Tb-161) for Advanced RadiotherapeuticsKinectrics and Isotopia have announced a partnership agreement under which Kinectrics will supply Gadolinium-160 (Gd-160) to enable Isotopia's production of Terbium-161 (Tb-161), a medical isotope showing promise for radiotherapeutics targeting prostate and neuroendocrine tumors. The agreement addresses a critical bottleneck in accessing Gd-160, a barrier that has long restricted the advancement of Tb-161-based treatments into clinical trials. Both companies expect the partnership to accelerate the development and potential commercialization of Tb-161-based radiotherapeutics.PR NewswireIsotopia Molecular Imaging Ltd. is thrilled to announce that Isoprotrace®, has received marketing authorization in the Netherlands (RVG 130527)Isotopia Molecular Imaging Ltd. announced that its product Isoprotrace® has received marketing authorization in the Netherlands, with Billev Pharma serving as the marketing authorization holder. This approval allows the radiopharmaceutical to be used for PET imaging in prostate cancer patients and represents a significant regulatory milestone for the company. Isotopia is currently pursuing similar approvals in other European countries, including Germany.